查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1601228

临床前 CRO 市场：按服务、应用和最终用户划分 - 2025-2030 年全球预测

Preclinical CRO Market by Services (Bioanalysis & DMPK Studies, Toxicology Testing), Application (Cardiovascular Disease, Dermatology, Gastrointestinal), End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年临床前CRO市场价值为62.5亿美元，预计到2024年将达到68.5亿美元，复合年增长率为9.68%，到2030年将达到119.5亿美元。

临床前合约组织 (CRO) 透过外包从标靶识别到临床前测试的广泛研究服务，在药物开发中发挥关键作用。临床前 CRO 范围涵盖广泛的服务，包括体外和体内模型、药物动力学、毒理学和生物分析测试。随着製药公司寻求加速药物开发过程，同时控製成本和应对复杂的监管环境，临床前 CRO 的需求和应用变得越来越突出。最终用途范围主要针对寻求专家指导和药物发现和验证设施的製药和生物技术公司、学术研究机构和政府机构。

主要市场统计
基准年[2023] 62.5亿美元
预测年份 [2024] 68.5亿美元
预测年份 [2030] 119.5亿美元
复合年增长率（%） 9.68%

临床前CRO市场的成长是由研发投资增加、药物发现方法的技术进步以及个人化医疗需求不断增长等因素所推动的。新的机会，例如将人工智慧和机器学习引入临床前测试，可以显着提高业务效率并提高临床结果的可预测性。此外，鑑于人们对生物来源药品的兴趣日益浓厚，扩大与生技药品和生物相似药相关的服务也是一个潜在的成长领域。然而，它们也面临着局限性和挑战，包括市场竞争、不断变化的监管要求以及动物测试的伦理问题。

创新的关键领域之一是替代测试模型的开发，例如器官晶片技术，它有望提供一种更道德、更精确的药物测试方法。此外，进一步整合数位平台以改善资料管理并加强 CRO 和赞助商之间的合作也可以推动成长。市场的本质是动态和竞争的，重点是策略联盟、併购，以增强我们的服务组合和全球影响力。为了在这一动态中取得成功，CRO 公司必须提供灵活和可自订的服务，投资最尖端科技以满足客户不断变化的需求，并在监管变化方面保持领先地位。

市场动态：揭示快速发展的临床前 CRO 市场的关键市场洞察

供需的动态交互作用正在改变临床前 CRO 市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助消费行为及其对製造业的影响。

  • 市场驱动因素
    • 製药和生物製药公司活性化研发活动以开发新药和治疗方法
    • 製药公司将药物开发业务外包给 CRO 的趋势日益明显
    • 个人化药物的开发日益受到关注
  • 市场限制因素
    • 与临床前 CRO 服务相关的高成本和耗时的限制
  • 市场机会
    • 不断进步的技术进步使临床前研究更有效率和成本效益
    • 生技药品（包括单株抗体、疫苗和细胞疗法）临床前研究的巨大潜力
  • 市场挑战
    • 国际监管机构的严格规定和指南

波特五力：驾驭临床前 CRO 市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解临床前 CRO 市场的外部影响

外部宏观环境因素在塑造临床前CRO市场的绩效动态方面发挥关键作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解临床前 CRO 市场的竞争格局

对临床前 CRO 市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位矩阵临床前CRO市场供应商绩效评估

FPNV定位矩阵是评估临床前CRO市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。四个象限清楚且准确地划分供应商，帮助使用者辨识最能满足其策略目标的合作伙伴和解决方案。

本报告提供了涵盖关键重点领域的全面市场分析：

1. 市场渗透率：对当前市场环境的详细回顾，包括行业主要企业的大量资料。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5.产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 製药和生物製药公司增加研发活动以开发新药和治疗方法
      • 製药公司将药物开发业务外包给 CRO 的趋势增加
      • 个人化医疗的发展日益受到关注
    • 抑制因素
      • 与临床前 CRO 服务相关的高成本和耗时的限制
    • 机会
      • 技术进步使预调查更有效率且更具成本效益
      • 单株抗体、疫苗和细胞疗法等生技药品预研究的巨大潜力
    • 任务
      • 国际监管机构制定的严格法规和准则
  • 市场区隔分析
    • 服务：毒理学测试服务的使用正在迅速增加，重点关注安全和监管合方面。
    • 最终用户：改变生物製药公司使用临床前 CRO 的方式
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境
  • 客户客製化

第六章临床前CRO市场：依服务分类

  • 生物分析和 DMPK 研究
  • 毒性试验

第七章 临床前 CRO 市场：依应用分类

  • 心血管疾病
  • 皮肤科
  • 胃肠道
  • 泌尿系统和女性健康
  • 血液学
  • 免疫疾病
  • 感染疾病
  • 代谢紊乱
  • 神经病学
  • 肿瘤学
  • 眼科
  • 呼吸系统疾病

第八章临床前 CRO 市场：依最终使用者分类

  • 生物製药公司
  • 政府和学术机构
  • 医疗设备公司

第九章美洲临床前CRO市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区临床前CRO市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲临床前CRO市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • CRO公司TriApex完成君联资本主导的C轮资金筹措
    • PsychoGenics 推出 eCube，一个用于新药发现的人工智慧平台
    • 普鲁士宣布大幅扩展临床前研究和开发，以加速药物安全决策
    • AmplifyBio 扩展了细胞疗法的表征并缩小了临床前开发的差距
    • Clinchoice 透过收购 CRO 继续扩张
    • QPS 在台湾开设新的预调查设施
    • CRO Avanir 收购明讯
    • Apax 收购 Porsolt 多数股权，支持公司的成长策略并成为临床前服务的全球领导者
    • Cryoport 宣布与 Syneos Health 建立策略合作伙伴关係，以推进细胞和基因治疗
    • Crown Biosciences 与 ERS ​​Genomics 宣布签署全球 CRISPR/Cas9 基因组编辑专利授权协议
    • Domain Therapeutics 与 Exprycyte 签署免疫肿瘤学领域合作协议
    • 赛扬扩大早期临床药理学部门
    • ClinChoice 在 E 轮融资中筹集 1.5 亿美元
    • Hella Biolab 宣布与 Charles River 签署全球独家授权合约
    • IonsGate 临床前服务和 InSilicoTrials 合作

公司名单

  • Phenos GmbH
  • Syneos Health, Inc.
  • Eurofins Scientific SE
  • Jubilant Biosys Ltd. byJubilant Pharmova Limited Company
  • Parexel International Corporation.
  • CTI Clinical Trial and Consulting, Inc.
  • Shanghai Medicilon Inc.
  • ICON PLC
  • Atuka Inc.
  • Gubra
  • MCI Group Holding SA
  • SGS SA
  • Immusmol SAS
  • PsychoGenics Inc.
  • Laboratory Corporation of America Holding
  • Hera Biolabs
  • IQVIA Inc.
  • Biotrofix, Inc.
  • Medpace Holdings, Inc.
  • Veristat, LLC
  • Crown Bioscience, Inc.
  • PharmaCircle LLC
  • PPD by Thermo Fisher Scientific Inc.
  • Sanofi SA
  • Celerion
  • BenchSci
  • SCiAN Services Inc.
  • Vimta Labs Limited
  • Transpharmation
  • Diag2Tec SAS
  • MD Biosciences
  • ImQuest BioSciences
  • QPS Holdings, LLC
  • Invivotek by Genesis Biotechnology Group, LLC
  • Intertek Group PLC
  • WuXi AppTec Co., Ltd.
  • 10x Genomics, Inc.
  • Novartis AG
  • AmplifyBio
  • Charles River Laboratories International, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Inotiv, Inc.
  • Bioserve Biotechnologies（India）PVT Ltd. by REPROCELL Inc.
Product Code: MRR-A339DAEFA51A

The Preclinical CRO Market was valued at USD 6.25 billion in 2023, expected to reach USD 6.85 billion in 2024, and is projected to grow at a CAGR of 9.68%, to USD 11.95 billion by 2030.

Preclinical Contract Research Organizations (CROs) play a crucial role in drug development by providing outsourced research services that range from target identification to preclinical testing. The scope of preclinical CROs encompasses a wide array of services, including in vitro and in vivo models, pharmacokinetics, toxicology, and bioanalytical testing. As pharmaceutical companies aim to accelerate their drug development processes while managing costs and navigating complex regulatory landscapes, the necessity and application of preclinical CROs have become more pronounced. The end-use scope predominantly covers pharmaceutical and biotechnology firms, academic research institutes, and government bodies seeking expert guidance and facilities for drug discovery and validation.

KEY MARKET STATISTICS
Base Year [2023] USD 6.25 billion
Estimated Year [2024] USD 6.85 billion
Forecast Year [2030] USD 11.95 billion
CAGR (%) 9.68%

Market growth for preclinical CROs is driven by factors such as increasing R&D investments, technological advancements in drug discovery methods, and an escalating demand for personalized medicine. Emerging opportunities, such as the adoption of AI and machine learning in preclinical studies, present avenues for significant operational efficiencies and improved predictability of clinical outcomes. Another potential growth area lies in expanding services related to biologics and biosimilars, given the rising interest in biologically-derived drugs. However, the market also faces limitations and challenges, including high competition, evolving regulatory requirements, and ethical concerns around animal testing.

One major area of innovation lies in the development of alternative testing models like organ-on-chip technologies, which promise a more ethical and precise approach to drug testing. Additionally, further integration of digital platforms to improve data management and increase collaboration between CROs and sponsors can also propel growth. The nature of the market is dynamic and competitive, with an increased focus on strategic partnerships, mergers, and acquisitions to enhance service portfolios and global reach. To thrive amidst these dynamics, CRO businesses should focus on offering flexible, customizable services and investing in cutting-edge technologies to meet the evolving needs of their clientele while staying ahead of regulatory changes.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Preclinical CRO Market

The Preclinical CRO Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing R&D activities by pharmaceutical and biopharmaceutical companies to develop new drugs & therapies
    • Rising trend of outsourcing drug development activities to CROs by pharmaceutical companies
    • Growing focus on the development of personalized medicines
  • Market Restraints
    • High cost and time-consuming constraints associated with preclinical CRO services
  • Market Opportunities
    • Growing advances in technologies to enable more efficient and cost-effective preclinical research
    • High potential for preclinical research for biologics, including monoclonal antibodies, vaccines, and cell therapies
  • Market Challenges
    • Stringent regulations and guidelines set by international regulatory authorities

Porter's Five Forces: A Strategic Tool for Navigating the Preclinical CRO Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Preclinical CRO Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Preclinical CRO Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Preclinical CRO Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Preclinical CRO Market

A detailed market share analysis in the Preclinical CRO Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Preclinical CRO Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Preclinical CRO Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Preclinical CRO Market, highlighting leading vendors and their innovative profiles. These include Phenos GmbH, Syneos Health, Inc., Eurofins Scientific SE, Jubilant Biosys Ltd. byJubilant Pharmova Limited Company, Parexel International Corporation., CTI Clinical Trial and Consulting, Inc., Shanghai Medicilon Inc., ICON PLC, Atuka Inc., Gubra, MCI Group Holding SA, SGS SA, Immusmol SAS, PsychoGenics Inc., Laboratory Corporation of America Holding, Hera Biolabs, IQVIA Inc., Biotrofix, Inc., Medpace Holdings, Inc., Veristat, LLC, Crown Bioscience, Inc., PharmaCircle LLC, PPD by Thermo Fisher Scientific Inc., Sanofi S.A., Celerion, BenchSci, SCiAN Services Inc., Vimta Labs Limited, Transpharmation, Diag2Tec SAS, MD Biosciences, ImQuest BioSciences, QPS Holdings, LLC, Invivotek by Genesis Biotechnology Group, LLC, Intertek Group PLC, WuXi AppTec Co., Ltd., 10x Genomics, Inc., Novartis AG, AmplifyBio, Charles River Laboratories International, Inc., F. Hoffmann-La Roche Ltd., Inotiv, Inc., and Bioserve Biotechnologies (India) PVT Ltd. by REPROCELL Inc..

Market Segmentation & Coverage

This research report categorizes the Preclinical CRO Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Services, market is studied across Bioanalysis & DMPK Studies and Toxicology Testing.
  • Based on Application, market is studied across Cardiovascular Disease, Dermatology, Gastrointestinal, Genitourinary & Women's Health, Hematology, Immunological Disorders, Infectious Diseases, Metabolic Disorders, Neurology, Oncology, Ophthalmology, and Respiratory Disorders.
  • Based on End-User, market is studied across Biopharmaceutical Companies, Government & Academic Institutes, and Medical Device Companies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing R&D activities by pharmaceutical and biopharmaceutical companies to develop new drugs & therapies
      • 5.1.1.2. Rising trend of outsourcing drug development activities to CROs by pharmaceutical companies
      • 5.1.1.3. Growing focus on the development of personalized medicines
    • 5.1.2. Restraints
      • 5.1.2.1. High cost and time-consuming constraints associated with preclinical CRO services
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing advances in technologies to enable more efficient and cost-effective preclinical research
      • 5.1.3.2. High potential for preclinical research for biologics, including monoclonal antibodies, vaccines, and cell therapies
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulations and guidelines set by international regulatory authorities
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Services: Burgeoning usage of Toxicology testing services focusing on the safety and regulatory compliance aspects
    • 5.2.2. End-User: Evolving usage of preclinical CRO by biopharmaceutical companies
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental
  • 5.5. Client Customization

6. Preclinical CRO Market, by Services

  • 6.1. Introduction
  • 6.2. Bioanalysis & DMPK Studies
  • 6.3. Toxicology Testing

7. Preclinical CRO Market, by Application

  • 7.1. Introduction
  • 7.2. Cardiovascular Disease
  • 7.3. Dermatology
  • 7.4. Gastrointestinal
  • 7.5. Genitourinary & Women's Health
  • 7.6. Hematology
  • 7.7. Immunological Disorders
  • 7.8. Infectious Diseases
  • 7.9. Metabolic Disorders
  • 7.10. Neurology
  • 7.11. Oncology
  • 7.12. Ophthalmology
  • 7.13. Respiratory Disorders

8. Preclinical CRO Market, by End-User

  • 8.1. Introduction
  • 8.2. Biopharmaceutical Companies
  • 8.3. Government & Academic Institutes
  • 8.4. Medical Device Companies

9. Americas Preclinical CRO Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Preclinical CRO Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Preclinical CRO Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. CRO Company TriApex Completes Series C Financing Round Led by Legend Capital
    • 12.3.2. PsychoGenics Launches eCube, a New AI-Enabled Platform for Drug Discovery
    • 12.3.3. Proscia Announces Major Expansion in Preclinical R&D to Drive Faster Drug Safety Decisions
    • 12.3.4. AmplifyBio Expands Cell Therapy Characterization, Fills Gap in Preclinical Development
    • 12.3.5. Clinchoice Continues Expansion with CRO Acquisition
    • 12.3.6. QPS opens an additional preclinical research facility in Taiwan
    • 12.3.7. CRO Avania Acquires MAXIS
    • 12.3.8. Apax Acquires a Majority Stake in Porsolt to Support its Growth Strategy and Become a Global Leader in Preclinical Services
    • 12.3.9. Cryoport Announces Strategic Partnership with Syneos Health to Advance Cell & Gene Therapies
    • 12.3.10. Crown Bioscience and ERS Genomics Announce Global CRISPR/Cas9 Licensing Agreement for Genome Editing Patents
    • 12.3.11. Domain Therapeutics and Explicyte Enter Partnership Agreement in Immuno-Oncology
    • 12.3.12. Celerion Expands Early Phase Clinical Pharmacology Units
    • 12.3.13. ClinChoice Raises USD 150 Million in Series E Round
    • 12.3.14. Hera BioLabs Announces Exclusive Global License With Charles River
    • 12.3.15. IonsGate Preclinical Services and InSilicoTrials Form Partnership

Companies Mentioned

  • 1. Phenos GmbH
  • 2. Syneos Health, Inc.
  • 3. Eurofins Scientific SE
  • 4. Jubilant Biosys Ltd. byJubilant Pharmova Limited Company
  • 5. Parexel International Corporation.
  • 6. CTI Clinical Trial and Consulting, Inc.
  • 7. Shanghai Medicilon Inc.
  • 8. ICON PLC
  • 9. Atuka Inc.
  • 10. Gubra
  • 11. MCI Group Holding SA
  • 12. SGS SA
  • 13. Immusmol SAS
  • 14. PsychoGenics Inc.
  • 15. Laboratory Corporation of America Holding
  • 16. Hera Biolabs
  • 17. IQVIA Inc.
  • 18. Biotrofix, Inc.
  • 19. Medpace Holdings, Inc.
  • 20. Veristat, LLC
  • 21. Crown Bioscience, Inc.
  • 22. PharmaCircle LLC
  • 23. PPD by Thermo Fisher Scientific Inc.
  • 24. Sanofi S.A.
  • 25. Celerion
  • 26. BenchSci
  • 27. SCiAN Services Inc.
  • 28. Vimta Labs Limited
  • 29. Transpharmation
  • 30. Diag2Tec SAS
  • 31. MD Biosciences
  • 32. ImQuest BioSciences
  • 33. QPS Holdings, LLC
  • 34. Invivotek by Genesis Biotechnology Group, LLC
  • 35. Intertek Group PLC
  • 36. WuXi AppTec Co., Ltd.
  • 37. 10x Genomics, Inc.
  • 38. Novartis AG
  • 39. AmplifyBio
  • 40. Charles River Laboratories International, Inc.
  • 41. F. Hoffmann-La Roche Ltd.
  • 42. Inotiv, Inc.
  • 43. Bioserve Biotechnologies (India) PVT Ltd. by REPROCELL Inc.

LIST OF FIGURES

  • FIGURE 1. PRECLINICAL CRO MARKET RESEARCH PROCESS
  • FIGURE 2. PRECLINICAL CRO MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PRECLINICAL CRO MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PRECLINICAL CRO MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL PRECLINICAL CRO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PRECLINICAL CRO MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL PRECLINICAL CRO MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS PRECLINICAL CRO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS PRECLINICAL CRO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES PRECLINICAL CRO MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES PRECLINICAL CRO MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC PRECLINICAL CRO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC PRECLINICAL CRO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA PRECLINICAL CRO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA PRECLINICAL CRO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. PRECLINICAL CRO MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. PRECLINICAL CRO MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PRECLINICAL CRO MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PRECLINICAL CRO MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PRECLINICAL CRO MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PRECLINICAL CRO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PRECLINICAL CRO MARKET DYNAMICS
  • TABLE 7. GLOBAL PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PRECLINICAL CRO MARKET SIZE, BY BIOANALYSIS & DMPK STUDIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PRECLINICAL CRO MARKET SIZE, BY TOXICOLOGY TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PRECLINICAL CRO MARKET SIZE, BY CARDIOVASCULAR DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PRECLINICAL CRO MARKET SIZE, BY DERMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PRECLINICAL CRO MARKET SIZE, BY GASTROINTESTINAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PRECLINICAL CRO MARKET SIZE, BY GENITOURINARY & WOMEN'S HEALTH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PRECLINICAL CRO MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PRECLINICAL CRO MARKET SIZE, BY IMMUNOLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL PRECLINICAL CRO MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL PRECLINICAL CRO MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL PRECLINICAL CRO MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL PRECLINICAL CRO MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL PRECLINICAL CRO MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL PRECLINICAL CRO MARKET SIZE, BY RESPIRATORY DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL PRECLINICAL CRO MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL PRECLINICAL CRO MARKET SIZE, BY GOVERNMENT & ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL PRECLINICAL CRO MARKET SIZE, BY MEDICAL DEVICE COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS PRECLINICAL CRO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES PRECLINICAL CRO MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC PRECLINICAL CRO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 51. AUSTRALIA PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. CHINA PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 55. CHINA PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. CHINA PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. INDIA PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 58. INDIA PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. INDIA PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. INDONESIA PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 61. INDONESIA PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. INDONESIA PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. JAPAN PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 64. JAPAN PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. JAPAN PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. MALAYSIA PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 67. MALAYSIA PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. MALAYSIA PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. PHILIPPINES PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 70. PHILIPPINES PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. PHILIPPINES PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. SINGAPORE PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 73. SINGAPORE PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. SINGAPORE PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. SOUTH KOREA PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 76. SOUTH KOREA PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. SOUTH KOREA PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. TAIWAN PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 79. TAIWAN PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. TAIWAN PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. THAILAND PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 82. THAILAND PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. THAILAND PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. VIETNAM PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 85. VIETNAM PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 86. VIETNAM PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA PRECLINICAL CRO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 91. DENMARK PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 92. DENMARK PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. DENMARK PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. EGYPT PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 95. EGYPT PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. EGYPT PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. FINLAND PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 98. FINLAND PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. FINLAND PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. FRANCE PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 101. FRANCE PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. FRANCE PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. GERMANY PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 104. GERMANY PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 105. GERMANY PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 106. ISRAEL PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 107. ISRAEL PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. ISRAEL PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 109. ITALY PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 110. ITALY PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 111. ITALY PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. NETHERLANDS PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 113. NETHERLANDS PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. NETHERLANDS PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 115. NIGERIA PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 116. NIGERIA PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. NIGERIA PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. NORWAY PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 119. NORWAY PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. NORWAY PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. POLAND PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 122. POLAND PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 123. POLAND PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. QATAR PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 125. QATAR PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. QATAR PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 127. RUSSIA PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 128. RUSSIA PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. RUSSIA PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. SAUDI ARABIA PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 131. SAUDI ARABIA PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. SAUDI ARABIA PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 133. SOUTH AFRICA PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 134. SOUTH AFRICA PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 135. SOUTH AFRICA PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. SPAIN PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 137. SPAIN PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. SPAIN PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. SWEDEN PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 140. SWEDEN PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 141. SWEDEN PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. SWITZERLAND PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 143. SWITZERLAND PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. SWITZERLAND PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. TURKEY PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 146. TURKEY PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 147. TURKEY PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED ARAB EMIRATES PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 149. UNITED ARAB EMIRATES PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 150. UNITED ARAB EMIRATES PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 151. UNITED KINGDOM PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 152. UNITED KINGDOM PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 153. UNITED KINGDOM PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 154. PRECLINICAL CRO MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 155. PRECLINICAL CRO MARKET, FPNV POSITIONING MATRIX, 2023